The University of MichiganNews Services
The University Record Online
search
Updated 10:00 AM Sept. 18, 2006
 

front

accolades

briefs

view events

submit events

UM employment


obituaries
police beat
regents round-up
research reporter
letters


archives

Advertise with Record

contact us
meet the staff
contact us
contact us

 
New switch can turn off tumor signal

The discovery of new cellular machinery leading to tumor cell growth in colorectal cancers points to a possible treatment. Researchers at the Life Sciences Institute (LSI) report in a study published Sept. 8 in the journal Cell that a signaling factor important in cell growth also may play a role in turning normal cells into tumors.

A team led by LSI research professor Kun-Liang Guan, assistant research scientist Ken Inoki, and School of Dentistry assistant professor Hong-Jiao Ouyang discovered that two signaling factors—Wnt and mTOR—both are connected to how cells grow.

Cells communicate instructions by trafficking molecules along specific pathways. Some pathways inhibit cell growth and some stimulate it. The mTOR signal encourages cell growth and normally is held in check by another set of signaling proteins. Guan's team, however, now shows that the Wnt signal gets in the way of that control and gives the green light to mTOR's drive to cancerous tumor development.

Because the Wnt signal is known to be active in most colon cancers, finding that it interacts with mTOR points to a possible therapeutic treatment for the disease with a U.S. Food and Drug Administration-approved drug, rapamycin, which inhibits the action of the mTOR pathway.

"The direct application from this research suggests that rapamycin could be a useful treatment for colon cancer, because now we know that Wnt and mTOR are connected," says Guan, who also is a professor of biological chemistry and a
MacArthur Foundation fellow.

He and his team long have studied the mTOR pathway, which processes information about cell status that regulates growth and proliferation. Much of their work has focused on a disease called tuberous sclerosis complex (TSC), which is marked by numerous benign tumors that invade vital organs. They've found that TSC tumor suppressors inhibit the mTOR pathway.

The latest research shows that Wnt can inactivate the TSC1 and TSC2 complex, allowing mTOR to encourage cell growth and perhaps enhance tumor development.

More Stories